Jun 13, 2019 - Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.
Jun 12, 2019 - Merck's (MRK) Keytruda is already approved for use in 15 cancer indications across 10 different tumor types in the United States.
Jun 06, 2019 - Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.
Sector: Health Care > Industry: Biotechnology: Commercial Physical & Biological Resarch